Abramson Cancer Center hematologic malignancies’ clinicians and researchers have led the way nationally for years; both in the care of patients with hematologic malignancies (blood cancer) and in its research.
Today, there's more hope than ever for those who face a blood cancer diagnosis.
Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.
Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute. It is through this research program that Penn has made significant advances in improving bone marrow and stem cell transplants and the care of patients with blood cancer.
The knowledge gained through our research allows us to better care for those with blood cancers.
To learn about what sets us apart, visit:
By the age of seven, Tanya Zekovitch already understood what it was like to be a cancer patient after being treated for Ewing's Sarcoma, a rare form of bone cancer. So when she was diagnosed with Acute Myeloid Leukemia in the summer of 2000, when she was still only in her early 20's, she felt lucky to find that Penn's Abramson Cancer Center offered patient support specialits and counselors to help patients cope with their diagnosis, not only to navigate the medical system, but also to address their emotional needs. Having benefited from counseling services when she was treated as a child, Tanya found Mindy Weismer, a Patient Service Coordinator, and they quickly developed a close relationship.
Focus On Blood Cancers and Bone Marrow Transplant Video
A patient education video with testimonies from our patients, doctors and researchers. Find out more about programs, treatment, research and care that is unique to the Abramson Cancer Center.